使用自动化高通量免疫分析评估 COVID-19 患者的抗体反应。
Clinical evaluation of the antibody response in patients with COVID-19 using automated high-throughput immunoassays.
机构信息
Department of Clinical Laboratory, Saitama Medical University Hospital, Saitama, Japan.
Department of Infectious Disease and Infection Control, Saitama Medical University, Saitama, Japan.
出版信息
Diagn Microbiol Infect Dis. 2021 Jul;100(3):115370. doi: 10.1016/j.diagmicrobio.2021.115370. Epub 2021 Mar 13.
Several automated high-throughput immunoassays for detecting anti-SARS-CoV-2 antibodies by a semi-quantitative approach have been commercialized. In this study, we describe the timeline of the antibody response in patients with RT-PCR-confirmed COVID-19. A total of 292 sequential serum samples from 33 Japanese patients were retrospectively analyzed using four test kits for SARS-CoV-2: the Abbott SARS-CoV-2 IgG assay (Abbott), Elecsys® Anti-SARS-CoV-2 assay (Roche Diagnostic), and VITROS® Anti-SARS-CoV-2 Total and IgG assays (Ortho Clinical Diagnostics). All automated immunoassays could equivalently identify positive sera collected within 2 weeks after symptom onset (99.3%-100%). In addition, the S protein-based automated immunoassay, the VITROS® Anti-SARS-CoV-2 Total assay, may play a complementary role in evaluating passive antibody therapies or vaccines against SARS-CoV-2, although further research is required.
已经有几种用于通过半定量方法检测抗 SARS-CoV-2 抗体的自动化高通量免疫测定法被商业化。在这项研究中，我们描述了经 RT-PCR 确诊的 COVID-19 患者的抗体反应时间过程。使用 Abbott SARS-CoV-2 IgG 测定试剂盒（Abbott）、Elecsys® Anti-SARS-CoV-2 测定试剂盒（罗氏诊断）和 VITROS® Anti-SARS-CoV-2 总抗体和 IgG 测定试剂盒（奥森多临床诊断），对 33 名日本患者的 292 份连续血清样本进行了回顾性分析。所有的自动化免疫测定法都可以等效地识别在症状出现后 2 周内采集的阳性血清（99.3%-100%）。此外，基于 S 蛋白的自动化免疫测定法，即 VITROS® Anti-SARS-CoV-2 总抗体测定法，可能在评估针对 SARS-CoV-2 的被动抗体疗法或疫苗方面发挥补充作用，尽管需要进一步的研究。
Zotero 插件